Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

Watch our Webinar on myeloma and infections

We held our latest webinar on September 11th, called Myeloma and infection: clinical and lived perspectives for myeloma patients, carers and advocates. Jackie Quinn, Myeloma Clinical Nurse Specialist, Belfast Trust presented on how myeloma and treatments increase infection risk, covering immunisations, bispecific antibody risks, and preventive medications. Mimi Quinn, myeloma patient from Ireland shared her personal…

Read more

Myeloma and infection: clinical and lived perspectives webinar

Myeloma Patients Europe (MPE) will host a webinar on “Myeloma and infection: clinical and lived perspectives” on Thursday, 11th September 2025 from 17:00 – 18:00 CEST. Aimed at myeloma patients, carers and patient advocates, the webinar will feature presentations on infection risk and prevention in myeloma, and a patient’s experiences of infection in myeloma. Jackie Quinn,…

Read more

The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patients

The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction (i.e., initial) treatment of newly diagnosed myeloma patients (NDMM) who are eligible for autologous stem cell transplant.  The decision follows an earlier positive recommendation of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP…

Read more

The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patients

Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP – their scientific advisory committee) on 23 May 2025. Marketing authorisation means that…

Read more

New guidelines for the treatment and the management of myeloma and smouldering myeloma

On July 7th, 2025, new clinical management guidelines for myeloma and smouldering myeloma were published in Nature Reviews Clinical Oncology by myeloma experts. These guidelines are written to guide doctors and healthcare professionals in myeloma and smouldering myeloma diagnosis, treatment and follow-up, based on the most up-to-date scientific knowledge. The last treatment guidelines were published in…

Read more
February

March 2026

April
MO
TU
WE
TH
FR
SA
SU
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Events for 1st March
No Events
Events for 2nd March
No Events
Events for 3rd March
No Events
Events for 4th March
No Events
Events for 5th March
No Events
Events for 6th March
No Events
Events for 7th March
No Events
Events for 8th March
No Events
Events for 9th March
No Events
Events for 10th March
No Events
Events for 11th March
No Events
Events for 12th March
No Events
Events for 13th March
No Events
Events for 14th March
No Events
Events for 15th March
No Events
Events for 16th March
No Events
Events for 17th March
No Events
Events for 18th March
No Events
Events for 19th March
No Events
Events for 20th March
No Events
Events for 21st March
No Events
Events for 22nd March
No Events
Events for 23rd March
No Events
Events for 24th March
No Events
Events for 25th March
No Events
Events for 26th March
No Events
Events for 27th March
No Events
Events for 28th March
No Events
Events for 29th March
No Events
Events for 30th March
No Events
Events for 31st March
No Events